Incyte study could bring lessons for cancer immunotherapy – BioPharma Dive
|
Incyte study could bring lessons for cancer immunotherapy
BioPharma Dive For all the clinical success of cancer drugs like Merck & Co.'s Keytruda, a good number of patients still don't see a major benefit from immunotherapy. Finding a way to expand the share who do has become the chief objective of drugmakers in the space … |
